cyrilzakka/clinical-trials huggingface dataset:
Pilates Mat Versus Cervical Stabilization Exercises on Balance in Young Adults With Forward Head Posture

see if there will be no statistical significant difference between the effects of Pilates mat versus cervical stabilization exercises on dynamic balance in young adults with forward head posture.

In modernized time, extended use of mobile phone and computers has increased anterior weight bearing of cervical spine leading to a variety of musculoskeletal disorders related to the neck by changing the biomechanical stress of cervical spine. Additionally, forward head posture (FHP) alters the center of gravity (COG) of the body that lead to mechanical modifications related to postural control in the torso and every joint. The body attempts to adapt to these changes by altering its balance control mechanisms; these adaptations decrease balance ability while performing different activities and increase the risk of falling and musculoskeletal injury.

Eligibility Criteria:
Inclusion Criteria:

* Subjects of both genders aged 18-25 years old with forward head posture will be included in this study.
* Subjects have forward head posture if the craniovertebral angle ≤ 50.
* Subjects complain non- specific neck pain for at least 3 months or at least two episodes of non-specific neck pain during the last three months.
* Normal body mass index (18- 24.9).

Exclusion Criteria:

* Subjects with any spinal problems.
* Temporo-mandibular disease.
* Subjects with experience in Pilates and who will not sedentary were excluded from the study.
* Previous surgery in the neck and shoulder regions
* Current participation in a structured exercises program
* Neurological symptoms of the upper extremities during screening tests (e.g., Spurling test and upper limb tension tests)
* Red flags suggesting of cancer, infection, vascular insufficiency.
* Cervical radiculopathy or myelopathy
Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study

This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.


Eligibility Criteria:
Inclusion Criteria:

* A patient dataset is deemed suitable for inclusion if the patient has a procedure where a Celect Platinum Vena Cava Filter is placed
* Subject has not previously participated in the Cook MDR-2126 study.

Exclusion Criteria:

* Patients will be excluded from enrollment if the patient or his/her legally authorized representative objects to collection and processing of his/her data or is not willing to sign the Informed Consent.
Black Resilient Caregivers

To determine the feasibility of an intervention to promote the physical and socioemotional health of African American (AA) families.

AA parents face unique racialized stressors which negatively impact their health and the health of their children. This heavy burden of chronic stress contributes to a high prevalence of anxiety and depression in AA parents. Parent stress negatively impacts child development and family health behaviors including diet and physical activity. A culturally-tailored intervention that addresses both AA parent stress and early childhood health and development has the potential to be more effective in promoting healthy family behaviors and AA parent mental health than traditional early childhood preventive care. Guided by AA parents and community members, the investigators propose to systematically co-develop a novel intervention using two frameworks: Centering and Superwoman Schema. The novel intervention will include group parent support, training in stress management and links to relevant community resources. The investigators will then determine the feasibility, acceptability, and limited efficacy of the adapted intervention in a pilot study.

Eligibility Criteria:
Inclusion Criteria:

* Identify as African American/Black
* Expecting a child due September, October or November 2024
* Feel comfortable discussing personal experiences and asking questions in front of a group of peers
* Access to zoom, preferably with video
* Live in North Carolina
* Infant and mom home within 96 hours of birth
Prevalence and Factors Associated With Postoperative Hypothermia in Mulago Hospital

Patient's sublingual temperature was measured postoperatively on entry to the recovery room.

Adult patients who underwent non-neurological and non-cardiac surgery had their sublingual temperature measured postoperatively on entry to the recovery room.

Eligibility Criteria:
Inclusion Criteria:

* All patients of 18 years and above, undergoing surgery and anaesthesia lasting longer than 30minutes.
* All patients of 18 years and above, undergoing elective and emergency non cardiac and non-neurological operations in Mulago National Referral Hospital.

Exclusion Criteria:

* Patients with contraindications to measurement of sublingual temperature
Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism

Ilaprazole is a novel proton pump inhibitor and metabolized by CYP3A4 and 2C19. Thus genetic polymorphisms of CYP3A4 and 2C19 may have effect on the pharmacokinetics and pharmacodynamics of Ilaprazole.

Effects of genetic polymorphisms on the pharmacokinetics or pharmacodynamics were measured in healthy Korean volunteers

Eligibility Criteria:
Inclusion Criteria:

* healthy adult volunteer between 20 and 45 years of age and within 20% of ideal body weight
* No congenital or acquired chronic disease
* appropriate for the study judging from examinations (hematology, chemistry, urinalysis and so on), vital sign and ECG results
* sign the informed consent form prior to study participation

Exclusion Criteria:

* received any metabolizing enzymes or transporters inducing or inhibiting drugs like barbiturates within 1 month prior to the date of first drug administration
* history of hypersensitivity against drugs or clinically significant allergic diseases
* abnormal laboratory results
* positive result for helicobacter pylori infection from the Urea Breath Test
* alcohol or drug abuser
* pregnant or lactating
* donated whole blood within 60days prior to the study
Ph II Early BC Pre-Surgical Biologic Study

A pre-surgery study to assess changes that occur in human breast cancer material and normal skin after a short course of treatment with Iressa.


Eligibility Criteria:
Inclusion Criteria:

* Invasive breast cancer, Aged 18 years or older, Not more than 28 days from initial diagnosis

Exclusion Criteria:

* Pregnant or lactating patients, Prior or current radiotherapy for breast cancer, Known allergy reaction to Iressa
Pipeline™ Flex Embolization Device With Shield Technology™ Clinical Study

The objective of the study is to assess the incidence of safety outcomes in patients treated with Pipeline™ Flex embolization device with Shield Technology™.


Eligibility Criteria:
Inclusion Criteria:

1. Subject has provided written informed consent using the IRB/EC-approved consent form and agrees to comply with protocol requirements.
2. Age 18-80 years.
3. Subject has already been selected for flow diversion therapy as the appropriate treatment.
4. Subject has an unruptured target intracranial aneurysm (IA).
5. Subject has a target IA located in the anterior or posterior circulation.

Exclusion Criteria:

1. Major surgery in the past 30 days.
2. Any known contraindication to treatment with the Pipeline™ Flex embolization device with Shield Technology™ per Instructions for Use.
3. Pregnant or breast-feeding women or women who wish to become pregnant during the length of study participation.
Understanding Participation Habits Among Plaque Psoriasis Patients

The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.

The data collected from this study will help improve future outcomes for all plaque psoriasis as well as those in under-represented demographic groups.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with plaque psoriasis
* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.

Exclusion Criteria:

* Refusal of consent
* Women of childbearing potential without a negative pregnancy test; or women who are lactating.
* Any serious and/or unstable pre-existing medical disorders
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss

Migraine and sudden sensorineural hearing loss(SSNHL) are two related disorders. A systemic steroid is usually used to treat SSNHL but the role of migraine prophylaxis medication remained unknown. Mehdi Abouzari et al. found a better improvement when combining topiramate and nortriptyline with steroids in a retrospective study. However, a prospective study with randomization is needed to elucidate the efficacy of these agents.

This is a clinical study using medication approved and currently prescribed in the clinic. The included patients were those who came to the clinic and were diagnosed with SSNHL within 14 days of onset. Those patients were asked whether they agreed to participate in this clinical trial. Patients who were diagnosed with SSNHL but were later found to be other diseases such as Meniere's disease and cerebellopontine angle will be excluded from this study.

The involved patients were randomized divided into two groups. Both groups received systemic steroids with/without intratympanic steroids. The experimental group receives additional oral topiramate for 6 weeks.

Follow-up time is at least 3 months.

This study is multi-center. Location of the study is performed at Chang gung memorial hospital Linkou branch, Taipei branch, Taoyuan branch, and New Taipei Municipal Tucheng Hospital.

Once the patients were diagnosed with SSNHL, detailed information of the clinical trial will be introduced. If the patient agreed to participate, he/she will be randomized. The experimental group receives additional oral topiramate for 6 weeks.

Both groups follow up at the clinic for at least 3 months. The pure tone audiometry and speech audiometry will be measured at the initial and end of follow-up.

Patients who were later diagnosed with cerebellopontine angle tumors, stroke, or Meniere's disease, will be excluded from this study.

The audiometry and other hearing outcomes will be analyzed at the end of the study. The treatment efficacy, and prognostic factors will be analyzed and reported. Data regarding adverse effects and drop-out will also be collected and reported.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 20
* Confirmed diagnosis of unilateral sudden sensorineural hearing loss(SSNHL)
* Treatment started 14 days within onset of SSNHL

Exclusion Criteria:

* Previous SSNHL history
* Previous middle ear disorder such as chronic otitis media, or previous ear surgery
* Meniere's disease and fluctuating hearing loss patients
* Pregnancy or trying to become pregnant
* Leukemia, hemodialysis, and patients who received chemotherapy before.
* Previous head and neck radiotherapy
* cerebellopontine angle tumors such as vestibular schwannoma
* Patients with moderate to severe hepatic insufficiency
* Patients with major depression disorder or suicide attempt
* Patients with glaucoma
Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants

This is a 24 month pilot project that will implement and evaluate an innovative program that integrates financial counseling with smoking cessation counseling for low-income immigrants.

This is a two-arm randomized, wait-list control study with 610 participants total: 600 patient participants and 10 staff participants. 600 smokers will be recruited to complete a 9-week intervention that integrates financial management and smoking cessation counseling. Participants will be randomized (300 per arm, stratified by site) to receive the intervention immediately after enrolling (Intervention Arm) or 6 months later (Waitlist Control Arm). Both arms will receive nicotine replacement therapy (NRT) for four weeks as part of their time in integrative counseling. Participants will be observed at baseline, 2 months, 6 months and 12 months to assess outcomes and their satisfaction with treatment.

Eligibility Criteria:
Inclusion Criteria:

* Smokes ≥5 cigarettes per day
* Born outside the U.S.
* Interested in receiving smoking and financial counseling
* Self-reported income below 200% of the current federal poverty level for a given household composition
* New York City resident
* English or Spanish language
* Able to provide informed consent, and
* Does not have a representative who manages his/her funds (to ensure the participant has the ability to manage household money). We will exclude participants who report being pregnant or breastfeeding (unable to receive NRT).

Hospital staff participants:

* Must be current medical or non-medical provider or administrator at Bellevue Hospital or New York University Lutheran Medical Center

Exclusion Criteria:

* We will exclude participants who report being pregnant or breastfeeding.
Prospective Research in Infants With Mild Encephalopathy

A multicenter observational pilot study will be conducted to determine the natural history of infants with early diagnosis (≤ 6 hrs of age) of mild neonatal encephalopathy (NE) who are not qualified for therapeutic hypothermia. The intervention includes: neurologic examination by using modified Sarnat score at ≤ 6 hrs of age, 24 hrs and before discharge home, amplitude-integrated electroencephalography (aEEG) at 6 ± 3 hrs of age, brain MRI at before discharge home to 30 days of age and follow-up at 18-22 months of age. Primary outcome is the percentage of mild NE infants with evidence of brain injury defined by the presence of at least 1 abnormality of brain MRI, aEEG or neurologic examination in the neonatal period. Secondary outcome is the percentage of brain MRI, aEEG and neurological exam abnormalities, seizure, length of hospital stay, need of gavage feeds or gastrostomy at discharge home, death and long-term outcome.

Globally, an estimated 1.8 to 7.7 infants per 1000 live term births suffer from perinatal asphyxia, which remains an important cause of neonatal encephalopathy (NE) and neurodevelopmental impairment. Over the last six years, several randomized control trials have demonstrated that prolonged and moderate therapeutic hypothermia (TH) reduces the rate of death or disability at 18 months of age among infants who survived. In these trials, infants were eligible if there was evidence of perinatal hypoxia-ischemia and a moderate or severe degree of encephalopathy on neurological evaluation performed at ≤ 6 hrs of age. However, it has been recognized that the level of NE may change over time. Preliminary and unpublished observations from our group indicated that some infants who were not classified as moderate or severe NE had neurological abnormalities at discharge or evidence of brain injury on MRI performed during the neonatal period. Unfortunately, precise data on the outcomes of this specific population is not clear. Since TH is not offered to this population, the outcomes of infants that do not qualify for TH based on neurological evaluation performed ≤ 6 hrs of life requires a more precise investigation.

Eligibility Criteria:
Inclusion Criteria:

* Infants with birth weight \> or = 1800g and gestational age \> or = 36 weeks AND
* Admission to neonatal intensive care unit (NICU) for possible hypothermia at \< or = 6hr of life

Exclusion Criteria:

* Infants with normal neurological evaluation
* Major congenital abnormalities
* Refusal of informed consent
* Infants who receive passive or active cooling prior to the NICU admission
* Infants that develop seizures or moderate/severe NE within the first 24 hr of life and are initiated on therapeutic hypothermia after 6 hr of life.
Inspiratory Effort in COVID-19

This study aims at assessing esophageal pressure in patients with acute respiratory failure due to COVID-19 undergoing non invasive respiratory support.


Eligibility Criteria:
Inclusion Criteria:

* COVID-19
* Acute respiratory failure undergoing non-invasive respiratory support

Exclusion Criteria:

* Need for immediate endotracheal intubation
* Chronic respiratory diseases
Addressing Social Determinants of Health & Diabetes Self-Management in Vulnerable Populations

In this pilot and feasibility study, the investigator will randomize 100 African-American, Hispanic, and/or Medicaid (all race/ethnicities) patients from KPNW with A1C ≥ 8 to one of two 6-month interventions: 1) patient navigation only; or 2) patient navigation + diabetes self-management training. Feasibility of a large-scale, pragmatic, randomized trial will be determined and preliminary effectiveness of treatment arms on A1C reduction among racial/ethnic minority and low-income patients with poorly managed diabetes will be examined.

The purpose of this feasibility study is to inform the design of a future large-scale, randomized trial that will test if there is added benefit to addressing both social and economic needs and diabetes self-management to improve diabetes management long-term among vulnerable populations. In this pilot, the investigator will randomize 100 African-American, Hispanic, and/or Medicaid (all race/ethnicities) patients from Kaiser Permanente Northwest (KPNW) with A1C ≥ 8 and poor follow-up in primary care to one of two 6-month interventions: 1) patient navigation only; or 2) patient navigation + diabetes self-management training. In both study arms, KPNW practice-embedded patient navigators will screen for medical, social and economic needs and connect participants to internal and external resources. In the second study arm, navigators will also refer participants to community health workers (CHWs) embedded in local community-based organizations, who will deliver diabetes self-management training. Feasibility of the full-scale trial will be based on several measures including recruitment, retention, success rate of referrals to navigators and CHWs, and whether medical, social, and/or economic needs are met. Qualitative interviews will be conducted with various stakeholders to assess intervention acceptability and determinants of implementation. Preliminary effects of A1C, diabetes-related care gaps, health care utilization, and medication adherence will also be examined. This pragmatic study design involves a collaborative effort among researchers, health system staff, health system senior leadership, and local community-based organizations. Findings from the full-scale trial will contribute critical knowledge on the most effective, sustainable model of care for integrating lay health workers in the efforts to improve diabetes management among high risk patient populations.

Eligibility Criteria:
Inclusion Criteria:

* Diabetes diagnosis
* Current Kaiser Permanente Northwest member
* African-American, Hispanic/Latino (English, Spanish-speaking, or bilingual), and/or a Medicaid recipient (from any racial or ethnic background)
* Age 18 or older
* Most recent hemoglobin A1C test of ≥ 8
* Endorses 1 or more social and/or economic need on the Your Current Life Situation assessment

Exclusion Criteria:

* Patients who are unable to provide informed consent due to cognitive or psychiatric impairment.
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness

This research study aims to develop a brief group-based treatment called Resilience Training for Teens, then to test how well it protects high school students with mild symptoms of depression, anxiety, or having unusual feelings from developing mental illnesses.


Eligibility Criteria:
Inclusion Criteria:

* Currently enrolled in 9th through 12th grade and between the ages of 14 and 19
* Endorsed at least one psychotic experience
* Provided contact information
* Have a parent or legal guardian who is able and willing to provide written informed consent (if under the age of 18)
* Have a parent or legal guardian who is able and willing to participate in a parent session
* Competent and willing to provide written informed assent (if under the age of 18) or consent (if age 18 or older)
* Able to communicate in English

Exclusion Criteria:

* Currently prescribed psychotropic medication (not including medications for attention deficit/hyperactivity disorder), regardless of adherence
* Currently obtaining psychotherapeutic intervention
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB102 injection in subjects with advanced malignancies.


Eligibility Criteria:
Inclusion Criteria:

* Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
* Male or female patient 18 to 75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy ≥12 weeks;
* Histologically or cytologically confirmed, locally advanced tumors, Priority will be given to subjects with HER2 positive solid tumor;
* Malignant tumor that failed from standard treatment or had no standard treatment;
* According to the RECIST 1.1 standard, patient with at least one evaluable lesion;
* The main organs function well;
* Male or female patient had no plans to become pregnant and voluntarily took effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug.

Exclusion Criteria:

* Concurrent secondary malignancy or other malignancy with no evidence of disease for more than 3 years;
* History of uncontrolled intercurrent illness;
* Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose;
* Patients with known symptomatic brain metastases;
* Receiving any other investigational agent within 4 weeks before first dose;
* Patients with severe hypersensitivity after the use of monoclonal antibodies
* History of interstitial lung disease or pneumonia;
* Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.
ERFs Game-based Assessment in AYAs: Validation of Game-based Assessment of Emotion Regulation Abilities

This activity will have the objective of establishing the validity of in-game emotion regulation abilities assessment for adolescents and young adults.

Each level of the REThink LIFE online game dedicated to training a specific ER skill has an assessment task for emotion recognition, stress reactivity, mindfulness and positive attention abilities. The aim of this study will be to investigate the validity of in-game performance measurements or scores as indicators of adolescents and young adults' emotion regulation abilities.

Eligibility Criteria:
Inclusion Criteria:

* adolescents and young adults with between 10 and 24 years old provided with written parental consent where applicable

Exclusion Criteria:

* intellectual disability or physical limitations precluded the use of the computer program